Literature DB >> 11709406

Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system.

F H Leenen1, R White, B Yuan.   

Abstract

To assess the possible contribution of the circulatory and cardiac renin-angiotensin system (RAS) to the cardiac hypertrophy induced by a beta-agonist, the present study evaluated the effects of isoproterenol, alone or combined with an angiotensin I-converting enzyme inhibitor or AT(1) receptor blocker, on plasma and LV renin activity, ANG I, and ANG II, as well as left ventricular (LV) and right ventricular (RV) weight. Male Wistar rats received isoproterenol by osmotic minipump subcutaneously and quinapril or losartan once daily by gavage. Plasma and LV ANGs were measured by radioimmunoassay after separation by HPLC. Isoproterenol alone decreased blood pressure, more markedly when combined with losartan or quinapril. Isoproterenol significantly increased LV and RV weight and total collagen. Neither losartan nor quinapril inhibited the increases in LV or RV weight. Losartan prevented the increase in RV collagen but enhanced the increase in LV collagen. Isoproterenol increased plasma renin, ANG I, and ANG II three- to fourfold. Isoproterenol combined with losartan or quinapril, caused marked further increases except for a significant decrease in plasma ANG II with quinapril. Isoproterenol alone did not increase LV ANG II and, combined with losartan or quinapril, actually decreased LV ANG II. These results indicate that isoproterenol-induced cardiac hypertrophy is associated with clear increases in plasma ANG II, but not in LV ANG II. Both losartan and quinapril lower LV ANG II below control levels, but do not prevent the isoproterenol-induced cardiac hypertrophy. These findings do not support a role for the circulatory or cardiac RAS in the cardiac trophic responses to beta-receptor stimulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11709406     DOI: 10.1152/ajpheart.2001.281.6.H2410

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  21 in total

1.  2-Methoxyestradiol Attenuates Angiotensin II-Induced Hypertension, Cardiovascular Remodeling, and Renal Injury.

Authors:  Eman Salah; Sheldon I Bastacky; Edwin K Jackson; Stevan P Tofovic
Journal:  J Cardiovasc Pharmacol       Date:  2019-03       Impact factor: 3.105

2.  Interactions between atrial natriuretic peptide and the renin-angiotensin system during salt-sensitivity exhibited by the proANP gene-disrupted mouse.

Authors:  Ekaterini Angelis; M Yat Tse; Stephen C Pang
Journal:  Mol Cell Biochem       Date:  2005-08       Impact factor: 3.396

Review 3.  Targeting signaling pathways in heart failure by gene transfer.

Authors:  Briain D MacNeill; Motoya Hayase; Roger J Hajjar
Journal:  Curr Atheroscler Rep       Date:  2003-05       Impact factor: 5.113

Review 4.  A pathway and network review on beta-adrenoceptor signaling and beta blockers in cardiac remodeling.

Authors:  Jihong Yang; Yufeng Liu; Xiaohui Fan; Zheng Li; Yiyu Cheng
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

5.  Central infusion of aldosterone synthase inhibitor prevents sympathetic hyperactivity and hypertension by central Na+ in Wistar rats.

Authors:  Bing S Huang; Roselyn A White; Monir Ahmad; Arco Y Jeng; Frans H H Leenen
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2008-05-21       Impact factor: 3.619

6.  Increased O2 consumption in excitation-contraction coupling in hypertrophied rat heart slices related to increased Na+ -Ca2+ exchange activity.

Authors:  Juichiro Shimizu; Daisuke Yamashita; Hiromi Misawa; Kiyoe Tohne; Satoshi Matsuoka; Bongju Kim; Ayako Takeuchi; Chikako Nakajima-Takenaka; Miyako Takaki
Journal:  J Physiol Sci       Date:  2008-12-11       Impact factor: 2.781

7.  Exercise training reduces cardiac angiotensin II levels and prevents cardiac dysfunction in a genetic model of sympathetic hyperactivity-induced heart failure in mice.

Authors:  M G Pereira; J C B Ferreira; C R Bueno; K C Mattos; K T Rosa; M C Irigoyen; E M Oliveira; J E Krieger; Patricia Chakur Brum
Journal:  Eur J Appl Physiol       Date:  2009-01-06       Impact factor: 3.078

8.  Tanshinone IIA protects against cardiac hypertrophy via inhibiting calcineurin/NFATc3 pathway.

Authors:  Xueying Tan; Jianping Li; Xinyue Wang; Nan Chen; Benzhi Cai; Gang Wang; Hongli Shan; Deli Dong; Yanju Liu; Xingda Li; Fan Yang; Xin Li; Peng Zhang; Xueqi Li; Baofeng Yang; Yanjie Lu
Journal:  Int J Biol Sci       Date:  2011-04-07       Impact factor: 6.580

9.  CpG-ODN attenuates pathological cardiac hypertrophy and heart failure by activation of PI3Kα-Akt signaling.

Authors:  Liang Yang; Xiangyu Cai; Jie Liu; Zhe Jia; Jinjin Jiao; Jincai Zhang; Changlin Li; Jing Li; Xiang D Tang
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

10.  Beta adrenergic overstimulation impaired vascular contractility via actin-cytoskeleton disorganization in rabbit cerebral artery.

Authors:  Hyoung Kyu Kim; Won Sun Park; Mohamad Warda; So Youn Park; Eun A Ko; Min Hee Kim; Seung Hun Jeong; Hye-Jin Heo; Tae-Hoon Choi; Young-Won Hwang; Sun-Il Lee; Kyung Soo Ko; Byoung Doo Rhee; Nari Kim; Jin Han
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.